Last reviewed: July 10, 2026
Last updated: July 10, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide produces measurable weight loss in most patients, with clinical trial data showing an average reduction of 15% body weight over approximately one year. However, the maximum weight loss you achieve depends on your genetics, adherence to therapy, and whether your treatment plan is personalized to your unique peptide pathways. PlexusDx uses precision testing to optimize your semaglutide protocol for better outcomes.
Average Weight Loss Results on Semaglutide Treatment
The SUSTAIN trial series established baseline expectations for semaglutide efficacy across different patient populations. Participants receiving 1.0 mg weekly achieved approximately 12–15% body weight reduction, while those on the highest doses experienced losses up to 18%. These averages represent patients with baseline obesity or overweight status combined with type 2 diabetes or cardiovascular risk factors.
Real-world outcomes reported by patients often fall within the 10–20% range over 12 months of consistent use. Some individuals plateau after 6–9 months, while others experience continued gradual loss over longer periods. The variance reflects differences in starting weight, metabolic rate, concurrent lifestyle changes, and individual genetic response to GLP-1 receptor signaling.
Factors That Determine Your Maximum Weight Loss Potential
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), and GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Lifestyle factors including dietary adherence, physical activity level, and sleep quality amplify or limit semaglutide's effectiveness. The medication suppresses appetite and reduces food cravings, but weight loss plateaus without caloric deficit maintenance. Starting body weight also matters—individuals with higher initial weights often experience larger absolute pound losses but similar percentage reductions.
Does Semaglutide Dosing Affect Maximum Weight Loss Outcomes
Higher semaglutide doses generally produce greater weight loss in dose-escalation studies, with 2.4 mg weekly showing superior results compared to 1.0 mg in the STEP trials. However, maximum tolerable dose depends on individual tolerability—gastrointestinal side effects increase at higher doses, leading some patients to remain on lower effective doses long-term. PlexusDx adjusts your compounded semaglutide dosing strategy based on tolerance and genetic response, ensuring you reach your optimal therapeutic level without unnecessary escalation.
The relationship between dose and weight loss is not linear indefinitely; most patients experience a plateau effect where further dose increases yield minimal additional loss. This plateau typically occurs between 12–18 months of consistent therapy. Timing dose adjustments with genetic insights from the Precision Peptide Genetic Test helps PlexusDx avoid ineffective escalations and focus on sustained, realistic outcomes.
Comparing Semaglutide to Other GLP-1 Options for Maximum Results
Semaglutide has demonstrated strong weight loss efficacy, but tirzepatide—a dual GIP/GLP-1 receptor agonist—shows numerically higher average losses (22% body weight in SURPASS trials) due to dual pathway activation. Some patients achieve greater results with tirzepatide, while others respond equally well or better to semaglutide alone. PlexusDx offers both compounded semaglutide injection ($189/month) and tirzepatide injection ($289/month) to match your genetic profile and goals.
The PlexusDx Precision Peptide Genetic Test identifies your predisposition to respond to GLP-1 versus GIP signaling by analyzing FTO rs9939609 and MC4R rs17782313 variants. Patients with specific genetic patterns may achieve maximum results faster with tirzepatide or dual-compound GLP-Squared therapy. Personalization prevents months of suboptimal treatment and accelerates safe progression toward your weight loss target.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the typical maximum weight loss someone can expect on semaglutide?
Clinical trials show average weight loss of 15% body weight over 68 weeks, with ranges from 10–20% in most patients. Some individuals achieve 20%+ losses, particularly those combining medication with structured dietary changes. Your personal maximum depends on starting weight, genetics, and treatment adherence—PlexusDx personalizes dosing to help you reach your individual potential.
Can you lose 50 pounds or more on semaglutide?
Yes, patients with baseline weights of 250+ pounds commonly lose 40–60+ pounds over 12–18 months on semaglutide, representing 15–20% body weight reduction. Absolute pound loss scales with starting weight. Maintaining caloric deficit through diet and activity maximizes outcomes; genetic factors influence how efficiently your body responds to GLP-1 signaling.
How long does it take to reach maximum weight loss on semaglutide?
Most significant weight loss occurs within the first 6–12 months as your dose escalates to therapeutic levels. A plateau typically develops between 12–18 months; continuing therapy maintains loss but rarely produces additional major decreases. PlexusDx's approach tracks your progress and adjusts treatment to sustain results without unnecessary dose escalation.
How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?
The Precision Peptide Genetic Test ($99 add-on after your first month) identifies GLP1R and GIPR variants that influence your appetite suppression intensity and metabolic response. These genetic insights help PlexusDx personalize whether semaglutide or tirzepatide aligns with your peptide pathway strengths, increasing your likelihood of achieving optimal outcomes. The test maps 49 peptides and 14 pathways for precision targeting.
What if I plateau on semaglutide—does increasing the dose help?
Plateaus are normal and often reflect genetic response limits rather than medication failure. Dose increases may provide modest additional loss in some patients but often trigger side effects without significant benefit. PlexusDx evaluates your genetic profile and tolerability to determine whether escalation, switching to tirzepatide, or dual-compound GLP-Squared therapy offers better outcomes for breaking through plateaus.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Who Should Not Take Mounjaro? Understanding Safety and Suitability
How to Switch from Trulicity to Mounjaro: A Patient’s Guide to a Smooth Transition